Lytix Biopharma AS – Mandatory notification of trade by close associate of primary insider

09 Jan 2026 11:50 CET

Oslo, Norway, 9 January 2026: Reference is made to the stock exchange
announcement published by Lytix Biopharma AS ("Lytix" or the "Company") earlier
today, on 9 January 2026, regarding a share issue of 6,826,200 shares (the
"Offer Shares") pursuant to a board authorisation granted by the Company's
extraordinary general meeting on 29 April 2025.

As of this date, the Company has been informed that Saturn Invest AS, a close
associate to primary insider Brynjar Forbergskog, subscribed for 2,222,222 Offer
Shares. Saturn Invest AS was allocated 2,222,222 Offer Shares at a price of NOK
9.00 per

Please see the attached form for further details about the transaction.

Disclosure regulation:
This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.

For more information, please contact:
Gjest Breistein, CFO
gjest.breistein@lytixbiopharma.com
+47 952 60 512

About Lytix Biopharma:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.

More information:
Access the news on Oslo Bors NewsWeb site

663387_Lytix - Saturn Invest AS - Mandatory Notification of trade by primary insiders and close associates.pdf